Program
SCTB35
A development code. Also written as “SCTB35 injection”.
Its studies are mostly in Lymphoma, Follicular · Lupus Erythematosus, Systemic · Lymphoma, Non-Hodgkin, led by Sinocelltech Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinocelltech Group | 44 open or running | phase 3since Apr 24, 2026 | Mar 12, 2024 | May 2027phase 2 · NCT06841042 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 12, 2024First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT06318884 · 76 planned · China
- Feb 11, 2025Phase 2 study in Lupus Erythematosus, SystemicNCT06841042 · 168 planned · China
- Apr 24, 20262 phase 3 studiesPhase 3 reachedNCT07562022, NCT07570823
Ahead
- May 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT06841042
- Nov 2027Primary completion: phase 3 study in Dendritic Cell Sarcoma, InterdigitatingNCT07570823
- May 2028Primary completion: phase 3 study in Lymphoma, FollicularNCT07562022
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07570823Dendritic Cell Sarcoma, Interdigitating · China | 3 | Recruiting | Nov 2027 | 101 |
| NCT07562022Lymphoma, Follicular · China | 3 | Recruiting | May 2028 | 93 |
| NCT06841042Lupus Erythematosus, Systemic · China | 2 | Recruiting | May 2027 | 168 |
| NCT06318884Lymphoma, Non-Hodgkin · China | 1 | Not yet recruiting | Oct 2026 | 76 |
How it is read
Names in the registry
- “SCTB35 injection”, 4 entries
Codes read as this program: SCTB35.
Conditions, from the studies’ own filings
- Lymphoma, Follicular, 1 study
- Lupus Erythematosus, Systemic, 1 study
- Lymphoma, Non-Hodgkin, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.